^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Peripheral T-cell Lymphoma
    Drug:Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study for combined with chidamide miantenance therapy after chidamide and azacitidine+CHOP sequential autologous hematopoietic stem cell transplantation in the first diagnosised III / IV stage peripheral T cell lymphoma

    Excerpt:
    ...Aged 18-65 treated first III / IV peripheral t-cell lymphoma (with the exception of NK/T lymphoma and ALK positive anaplastic large cell lymphoma), gender not limited; 2. ...
    Trial ID:
    ChiCTR2100043966
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)

    Excerpt:
    ...Pathologically diagnosed as peripheral T cell lymphoma (PTCL) according to WHO 2008 classification criteria（NK/T cell lymphoma, ALK positive anaplastic large cell lymphoma and granuloma fungoides excluded）; 2....
    Trial ID:
    NCT03268889
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    Chidamide with Azacitidine and CHOP Treatment Plus Autologous Transplantation, Followed By Maintenance with Chidamide for Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Interim Analysis of a Prospective,Single Center, Single-Arm, Phase 2 Trial

    Published date:
    11/03/2022
    Excerpt:
    We enrolled newly diagnosed PTCL patients (NK/T lymphoma and ALK positive T cell lymphoma were excluded) and used 21-day Chi+AZ-CHOP regimen...At interim assessment after cycle 4 induction therapy (n=13), the ORR was 69% with CR at 46%.
    Secondary therapy:
    CHOP + azacitidine
    DOI:
    https://doi.org/10.1182/blood-2022-166738